Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Do you really want to delete this prezi?
Neither you, nor the coeditors you shared it with will be able to recover it again.
Make your likes visible on Facebook?
You can change this under Settings & Account at any time.
Transcript of Vascular Grafts
BIEN 010 Section 021
•What We Learned
(cc) image by anemoneprojectors on Flickr
Cardiovascular Disease affects 26.8 million adults in the U.S.
Statistic is still on the rise.
Bioengineers need to find how to reduce the deaths caused by cardiovascular disease.
Unlike other treatment options vascular grafts enable doctors to quickly repair damaged vessels.
Causes of Death
(cc) image by anemoneprojectors on Flickr
Annual Deaths in 2009
To address the current Dacron graft that is on the market and attempt to solve its problems and criticisms.
Specific goals of the project:
•Improve the durability of the graft.
•Avoid clotting and breakage at the points of connection.
•Reduce poor blood flow that is caused by the graft.
Cardiovascular Disease = Having damaged arteries and veins.
Damage can result from:
Breakage of vessels due to aneurysms (ballooning of weakened vessel walls)
Failure of blood vessels over time.
Diabetes, high blood pressure, high cholesterol, and smoking.
Solution = Vascular Grafts
A graft is not a complete replacement but will serve its purpose by acting as a blood vessels to help continue blood flow.
Vascular Grafting is the use of biological/synthetic blood vessels to replace damaged, natural ones.
Deaths, caused by restricted vessels, can be reduced.
Types of Grafts:
To patch up damaged vessels and avoid allografting and autografting.
To replace extremely damaged portions of blood vessels. Without replacement, the patient would most certainly die.
So What Was Done in the Past?
Vascular Surgery was defined by Alexis Carrel.
Vascular Grafts, made out of Vinyon-N Cloth, first used by Arthur Voorhees.
Dacron, a synthetic vascular graft, was used and developed by Dr. De Bakey
Hyperplasia (increase in number of cells) at the distal and proximal end causes stenosis (narrowing of blood vessels) and thrombosis (blood clotting) of arterial bypass grafts.
Caused by compliance mismatch between the graft and artery and leads to stress.
Formation of aneurysms after graft implantation:
•Formed by thrombosis (blood clots due to blood platelets attaching to the wall).
• Symptoms are hard to detect and possible only when patient feels symptoms such as pain.
•Aneurysms can expand greatly.
•Failure to treat can lead to rupture and bleeding.
•Failure of Dacron grafts caused by material fatigue (gradual breakdown of individual fibers = weak prosthetic fabric).
Much improvements needed on today's grafts still .
So, some problems need solutions for current grafts.
True and False Aneurysms
Formation of Clots
Distal Embolization (Decreased blood flow) caused by Occlusions (Clotting of the blood).
Breakages and leakage of blood vessels at the site of anastomisis (the connections of two blood vessels).
Additional blood clots may form after the Heparin dissolves away.
Addition of Heparin.
Reinforcement of anastomosis site using drug eluting stents.
Dissolving layer that releases Heparin.
Results: Better blood flow through the veins by the thinning of the blood, thus clearing the occlusions.
•May cause profuse bleeding as well as headaches, dizziness, and chest pain.
•Can be minimized by the use of low molecular weight heparin (LMWH).
• The Heparin will eventually run out.
Results: The structure will be less likely to break or allow blood to leak through.
Coated with Heparin
Adding stents will cause scar tissue formation.
The blood vessel must be of at least a certain size.
Dacron Graft, bonded with Heparin
Degradable Polylactic Acid with Heparin
Results: Blood clots may be avoided for a longer duration of time, without subjecting the rest of the body to blood thinners.
Polyactic acid may degrade sooner than expected, releasing a larger dose of Heparin which may result in bleeding .
The degrading of PLA (though very slow) is determined by its environmental factors, so there is no control over degradation.
•$64 per 0.8ml of Low Molecular Weight Heparin.
•About $410 Dacron graft.
•$12 per lb polyactic acid.
•$1000 per stent.
Blood clotting, True and False Aneurysms, and eventual disappearance of Heparin.
Use of Heparin, addition of stents at the sites of aneurysms, and usage of a polyactic acid layer to introduce Heparin over time.
Increased blood flow, a reduced blood loss due to aneurysms, and increased protection against blood clots.
Synthetic grafts still fail eventually.
Future graft will be biodegradable and allows regeneration of blood vessel.
What We Learned
•Most products are not perfect
•Many require several improvements
•However, some improvements have side effects, so balance between what is improved and what is worsened is key.
•Bioengineering is not easy!!
•Akari, Bhajat. Personal interview. 2011.
•“Aneurysms in Vessel.” Photo. Belsurg 2005 17 Nov. 2011.
•“Aortic Aneurysm.” Photo. Medline Plus 01 Aug. 2011 17 Nov. 2011 <http://www.nlm.nih.gov/medlineplus/ency/imagepages/18072.htm>.
•“Applications in Cardiology.” Utah BIEN. Web. 04 Nov. 2011. http://www.belsurg.org/uploaded_pdfs/105/105_249_255.pdf.
• “Atherosclerosis in Artery.” Photo. University of Virginia Health System 17 Nov. 2011 <http://uvahealth.com/services/vascular-center/treatment/32867>.
•Astete, C. E. and Sabliov, C. M. (2006). "Synthesis and characterization of PLGA nanoparticles". Journal of Biomaterials Science - Polymer Edition 17 (3): 247–289.
•“Balance.” Photo. Wikimedia 22 Jun. 2008 18 Nov. 2011 <https://upload.wikimedia.org/wikipedia/commons/thumb/f/f9/Balance_icon.svg/256px-Balance_icon.svg.png>.
•“Blood Circulation Diagram.” Photo. Pratikka1 17 Nov. 2011 < http://pratikka.com.br/diagram-of-human-blood-flow&page=5>.
•“Blood Clot Diagram.” Photo. Wikipedia 14 Dec. 2006 17 Nov. 2011 < http://en.wikipedia.org/wiki/File:Blood_clot_diagram.png>.
•“Blood Flow in Arteries.” Photo. eHealth MD 28 Jun. 2011 17 Nov. 2011 <http://ehealthmd.com/content/what-complications-can-occur>.
• Carlino, Mauro. "Prevention of Distal Embolization During Saphenous Vein Graft Lesion Angioplasty : Experience With a New Temporary Occlusion and Aspiration System." Circulation. American Heart Association, 1999. Web. 04 Nov. 2011. <http://circ.ahajournals.org/content/99/25/3221.full>.
•“Cobalt Chromium Stent.” Photo. Abbot Vascular 17 Nov. 2011 <http://www.abbottvascular.com/us/multi-link-vision.html#overview>.
•“Comparison Between Vacron Graft and Real Vessel.” Photo. Gore.com 2011. 03 Nov. 2011 <http://www.gore.com/en_xx/products/medical/surgical/vascular/vascular.html>.
•Creemers E, Deprez M, Limet R, Van Damme H. "Intrinsic Structural Failure of Polyester (Dacron) Vascular Grafts. A General Review."PubMed.org. May 2005. Web. 03 Nov. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/16018516>.
•“Dacron Graft.” Photo. Perouse Medical 17 Nov. 2011 <http://www.perousemedical.com/gb/produit_7_66.html>.
•“Death Chart.” Chart. Drug War Facts 17 Nov. 2011 < http://drugwarfacts.org/cms/?q=node/30>.
•Dr. Svensson, Lars. “Photograph of Dacron Aortic Graft.” Photo. Cleveland Clinic 2011. 03 Nov. 2011 <http://my.clevelandclinic.org/heart/disorders/aorta_marfan/marfansurgery_actual.aspx>. 20
•Friedman, Steven G., Richard S. Lazzaro, Laurence N. Spier, Carmine Moccio, and Anthony J. Tortolani. "A Prospective Randomized Comparison of Dacron and Polytetrafluoroethylene Aortic Bifurcation Grafts." Science Direct. 15 June 2006. Web. 08 Nov. 2011.
•"Heparin." RxList. 14 Oct. 2010. Web. 11 Nov. 2011. http://www.rxlist.com/heparin-drug.htm.
•"Heparin Sodium." Drugstore Online Pharmacy. Web. 17 Nov. 2011. <http://www.drugstore.com/heparin-sodium-porcine/1ml-vial-10000unitml-solution/qxn63323054201>.
•“How Dacron Graft is Connected.” Photo. The Annals of Thoracic Surgery 13 Aug. 2004. 03 Nov. 2011 <http://ats.ctsnetjournals.org/cgi/content/full/79/3/796>.
•Hu, Jiang, Xuan Sun, Haiyun Ma, Xie Changqing, Eugene C. Y., and Peter X. Ma. "Porous Nanofibrous PLLA Scaffolds for Sascular Tissue Engineering." PubMed Central. 31 July 2010. Web. 08 Nov. 2011. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930107/?tool=pubmed>.
•H.V. Damme, M. Deprez, E. Creemers, and R. Limet. “Intrinsic Structural Failure of Polyester (Dacron) Vascular Grafts. A General Review.” Journal Acta Chir Belg. Vol 105, 2005, pp.249-255.http://www.sciencedirect.com/science/article/pii/S0039606005802235..
•Lin, P. H., C. Chen, R. L. Bush, Q. Yao, A. B. Lumsden, and S. R. Hanson. "Small-caliber Heparin-coated EPTFE Grafts Reduce Platelet Deposition and Neointimal Hyperplasia in a Baboon Model." National Center for Biotechnology Information. June 2004. Web. 10 Nov. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/15192575>.
• Millisano, Germano. "Endovascular Treatment of a Noninfected Anastomotic Juxtarenal Aortic Aneurysm." PubMed Central. Texas Heart Institute, Houston, 2000. Web. 04 Nov. 2011. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC101114/>.
•"New Heart Stent Carries Hefty Price Tag." CBS News. 05 Mar. 2009. Web. 18 Nov. 2011. <http://www.cbsnews.com/stories/2003/04/24/health/main550936.shtml>.
•"Patient-specific Stem Cells: Major Step Toward Cell-based Therapies for Life-threatening Diseases." Science Daily. 06 Oct. 2011. Web. 09 Nov. 2011. <http://www.sciencedaily.com/releases/2011/10/111006090029.htm>.
•P.D. Ballyk, C. Walsh, J. Butany, and M. Ojha. “Compliance Mismatch may Promote Graft-artery Intimal Hyperplasia by Altering Suture-line Stresses” Journal of Biomechanics. Vol. 31, 1998, pp. 229-237.
•Peck, M. "The Evolution of Vascular Tissue Engineering and Current State of the Art."PubMed Central. Cytograft Tissue Engineering Inc., 13 Oct. 2011. Web. 04 Nov. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/21996786>.
•Pettis, Bre. "Bio-Friendly Plastic for Your MakerBot – Polylactic Acid." MakerBot Industries. 09 Jan. 2010. Web. 17 Nov. 2011. <http://www.makerbot.com/blog/2010/01/09/bio-friendly-plastic-for-your-makerbot-polylactic-acid/>.
•“Picture of Dr. de Bakey.” Photo. Poor William’s Almanac 07 Sep. 2009 17 Nov. 2011 <http://www.poorwilliam.net/al-090709.html>.
•“Proposed Mechanism for Vascular Transformation.” Photo. Proceedings of the National Academy of the Sciences of the United States 26 Jan. 2010 18 Nov. 2011 <http://www.pnas.org/content/107/10/4669/F5.large.jpg>.
•Schürmann, K. "Iliac Arteries: Plain and Heparin-coated Dacron-covered Stent-grafts Compared with Noncovered Metal Stents--an Experimental Study." Radiology. Radiology. Web. 04 Nov. 2011. <http://radiology.rsna.org/content/203/1/55.short>.
•“SEAL Bifurcated Stent Graft.” Photo. S&G Biotech Inc. 17 Nov. 2011 <http://www.sngbio.com/v2/en_prod_10.php>.
•“Stress at Connection Site.” Photo. SciVerse Science Direct 19 December 1997 17 Nov. 2011 <http://www.sciencedirect.com/science/article/pii/S0197397597001115>.
•“Stong Arm.” Photo. Stitched Up Stikers 17 Nov. 2011 < http://www.stitchedupderbystickers.com/products-page/stickers/strong-arm/>.
•Swathi, Ravi, and Elliot L. Chaikof. "Biomaterials for Vascular Tissue Engineering." PubMed Central. 05 Jan. 2010. Web. 08 Nov. 2011. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822541/>.
•"Tissue Engineered Vascular Grafts: History." Drexel University Pages. Web. 03 Nov. 2011. <http://www.pages.drexel.edu/~cas95/History.html>.
Blood vessels; includes arteries